01 / 07 / 2020
Initiate the new year with our next in vitro shuttle session on our validated M2 macrophage suppression assay, which will take place by early February – thereby providing an opportunity to timely and cost-effectively assess novel immunotherapeutics.
12 / 03 / 2019
We will be attending the ESMO Immuno-Oncology Congress in Geneva, from December 11 to 14, 2019. We will be glad to take this opportunity to meet you there, describe our service offerings and approach your research projects.
10 / 28 / 2019
We are proud to announce that the French Ministry for Higher Education and Research has recognised Explicyte / Immusmol SAS as a "Credit Import Recherche" (CIR) approved research and development service provider.
10 / 24 / 2019
Nous sommes heureux de vous informer que le Ministère de l’Enseignement Supérieur, de la Recherche et de l’Innovation a remis un avis favorable au dossier de demande d’agrément Crédit Impôt Recherche déposé par Explicyte / Immusmol SAS.
05 / 21 / 2019
By setting new facilities within the cancer center “Institut Bergonié”, Explicyte - in addition to its preclinical research capabilities - strengthens its development towards clinical translational research, to provide new services based on multiparametric experimental biomarker analysis, for target identification and monitoring of the immune response in the context of clinical trials.
04 / 23 / 2019
Our syngeneic glioma mouse model, based on the intracranial inoculation of Luc2-expressing GL261 cells and bioluminescence imaging for tumor growth monitoring, represents a suitable tool for chemo- and immunotherapy assessment. It closely mimics the human disease in terms of tumor progression and anti-tumor response, and recapitulates glioblastoma characteristic features including among others tumor immune cell infiltration and tumor-induced immunosuppression.
03 / 25 / 2019
Bordeaux, FRANCE, March 24, 2019: Explicyte and Institut Bergonié, have entered into a collaboration to conjointly drive a translational research program aiming at identifying resistance mechanisms to immune checkpoint inhibitors in cancer patients.